Triera Biosciences

What Triera Biosciences does

Triera Biosciences is a Canadian biotechnology company and wholly-owned subsidiary of Zentek Ltd. (TSX-V: ZEN, Nasdaq: ZTEK), operating an aptamer-based molecular recognition platform built on an exclusive 20-year worldwide license from McMaster University covering SELEX (Systematic Evolution of Ligands by EXponential Enrichment) technology. The platform combines custom aptamer discovery, electrochemical biosensor engineering, and in-house machine-learning signal classification, with three lead McMaster researchers providing the scientific backbone (588 combined publications). The company's aptamer-sensor-ML architecture was validated at 100% classification accuracy on 172 real patient samples, published in ACS Sensors in January 2025, and serves as the foundation for a five-target diagnostic pipeline (Influenza A, Syphilis, COVID-19, Norovirus, and VEGF cancer biomarker) with combined addressable market stated to exceed US$4.5 billion.

Triera's commercial model is a development-on-demand contract research organization (CRO) launched in March 2026, with engagements priced between C$50,000 and C$500,000 per custom aptamer discovery project on weeks-to-months timelines. The company retains ownership of underlying intellectual property while clients receive usage licenses, creating a compounding IP portfolio. Revenue streams include custom aptamer services for pharmaceutical, biotechnology, and diagnostics companies in Canada, the United States, and Europe, and government-funded R&D through Innovative Solutions Canada and Ontario Centres of Innovation (a C$300,000 Collaborate 2 Commercialize award for seasonal influenza treatment candidates was secured in April 2026). The headcount is 1–10, with research operations anchored at McMaster University in Hamilton, Ontario, and corporate activities at the parent Zentek headquarters in Guelph, Ontario.

Name

Triera Biosciences

Legal name

Zentek Ltd.

Website

https://triera.ca

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Triera Biosciences is a Canadian aptamer-based biotechnology CRO and Zentek Ltd. subsidiary that provides custom molecular recognition tools, electrochemical biosensors, and ML signal classification to pharma, biotech, diagnostics, and government customers in North America and Europe under an exclusive 20-year McMaster University license.

Ownership category

akta.pro rank

Product category

Aptamer Biotechnology Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Aptamer discovery services
• Biosensor development
• Molecular diagnostics platform
• Contract research organization
• Custom molecular recognition

Headquarters

HQ city

Guelph

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. CRO Services - Custom Aptamer Discovery: Client-funded contract research organization services for custom aptamer development. Triera executes full stack: target identification, SELEX discovery, sensor engineering, ML classification, and validation. Asset-light model with IP retained by Triera while client receives usage license.
2. Government Research Contracts: Government-funded R&D programs including Innovative Solutions Canada and Ontario Centres of Innovation Collaborate 2 Commercialize agreements. Non-dilutive funding to advance proprietary therapeutic candidates.
3. Diagnostic Product Pipeline: Five validated diagnostic targets in development pipeline targeting influenza A, syphilis, COVID-19, norovirus, and VEGF cancer biomarker. Platform reusable across targets - each additional target adds a product without platform rebuild.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Triera Biosciences operates an aptamer-based Contract Research Organization (CRO) delivering full-stack custom molecular recognition services to pharmaceutical, biotechnology, diagnostics, and government clients. Services span target identification, SELEX-based aptamer discovery, electrochemical biosensor engineering, machine-learning signal classification, and clinical validation, supported by an exclusive 20-year McMaster University license covering SELEX aptamer discovery technology and related IP.

Product overview

Triera Biosciences operates as an aptamer Contract Research Organization (CRO) offering custom molecular recognition tools for pharmaceutical and biotech companies. The platform consists of three integrated service lines: (1) Custom Aptamer Discovery services ranging from $50K–$500K per project for full-stack development from target identification through validation; (2) Government Contract Programs funded by pandemic preparedness initiatives including DRDC defence diagnostics; and (3) a Validated Diagnostic Pipeline of five rapid diagnostic products (Influenza A, Syphilis, COVID-19, Norovirus, and VEGF/Cancer) all built on the same reusable aptamer-electrochemical sensor-ML classification platform. The platform was validated at 100% ML accuracy on 172 real patient samples (ACS Sensors, January 2025) and is backed by an exclusive 20-year McMaster University license covering SELEX technology and related IP. Combined addressable market across the five diagnostic targets exceeds $4.5 billion.

Differentiator

Problem solved

Functional benefit

Brands

• ZenGUARD: Patented graphene oxide coating technology for HVAC air filters, surgical masks, and air-contact surfaces. Alters surface topography to increase air disruption without increasing pressure differential.
• ZenFire
• ZenICE
• ZenArmor
• GraphGel

Products and services

• Custom Aptamer Discovery Service Full-stack custom aptamer development engagements for pharmaceutical and biotech clients covering target identification, SELEX aptamer discovery, electrochemical sensor engineering, machine-learning classification, and validation. Projects priced at $50,000-$500,000 per engagement with timelines in weeks to months; Triera retains commercial IP rights while client receives a usage license.
• Government Contract Programs Aptamer-based countermeasure development funded by government pandemic preparedness programs, including engagements with Defence Research and Development Canada (DRDC) for defence diagnostics and Innovative Solutions Canada. Client-funded R&D advancing proprietary therapeutic and diagnostic candidates.
• Influenza A Rapid Diagnostic Aptamer-based rapid diagnostic targeting Influenza A virus (respiratory pathogen) for seasonal epidemics and pandemic preparedness. Built on the reusable aptamer-electrochemical sensor-ML classification platform; adaptable to new variants in weeks versus months for antibody re-validation.
• Syphilis Rapid Diagnostic Aptamer-based rapid diagnostic for Treponema pallidum (sexually transmitted infection). Room-temperature stable test viable where antibody-based equivalents are not, addressing rising incidence across North America and Europe.
• COVID-19 Rapid Diagnostic Aptamer-based rapid diagnostic for SARS-CoV-2 built on the same reusable aptamer-sensor-ML platform. Structural advantage over antibody-based tests through weeks-scale adaptability to new variants.
• Norovirus Rapid Diagnostic Aptamer-based rapid diagnostic for Norovirus (gastrointestinal virus) enabling point-of-care detection in healthcare facilities, schools, cruise ships, and outbreak settings. Temperature stability is the key differentiator over antibody-based alternatives.
• VEGF Cancer Diagnostic Aptamer-based VEGF (Vascular Endothelial Growth Factor) detection platform for oncology applications. Liquid biopsy tool for tumor angiogenesis monitoring and treatment response assessment across multiple cancer types.

Quantifiable outcome

• 100% ML classification accuracy on 172 real patient samples
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and major.

• Ontario Centres of InnovationcoreStrategic or Co-development Partner · 14 April 2026Collaborate 2 Commercialize agreement worth approximately $300,000 to advance proprietary seasonal influenza treatment candidates targeting H1N1 and H3N2 strains. Program includes GLP-style toxicology studies oriented toward Health Canada regulatory dialogue.
• McMaster UniversitycoreStrategic or Co-development PartnerExclusive 20-year worldwide license from McMaster University covering aptamer discovery via SELEX technology and related intellectual property. Three lead McMaster researchers with 588 combined publications support the platform. Collaboration on electrochemical sensor development and ML classification.
• Government of Canada - Innovative Solutions CanadacoreStrategic or Co-development PartnerCompleted Government of Canada contract through Innovative Solutions Canada program for developing an aptamer-based asset targeting H5N1 avian influenza. Non-dilutive funding supporting R&D costs.
• Defence Research and Development Canada (DRDC)majorStrategic or Co-development PartnerActive government relationship for defence diagnostics applications. Part of Triera's positioning as preferred domestic partner for government pandemic preparedness programs.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aptamer Group: Aptamer Group is a UK-based CRO offering custom aptamer discovery services and Optimer binders for diagnostics, therapeutics, and research reagents. Direct competitor for Triera's CRO services and aptamer-based diagnostic platform offerings.
• SomaLogic (Standard BioTools): SomaLogic operates an aptamer-based (SOMAmer) proteomics platform for biomarker discovery and diagnostics. Most directly comparable peer to Triera because both use aptamer-based molecular recognition for biomarker and diagnostic applications, and both compete for pharma/biotech CRO services budgets.
• NeoVentures Biotechnology: NeoVentures is a Canadian aptamer discovery and development CRO serving pharmaceutical and diagnostic customers. Direct aptamer CRO peer with overlapping service offerings and similar target customer segments.
• Aptagen: Aptagen provides custom aptamer-based diagnostic and biosensor development services to research and commercial customers. Direct CRO peer in aptamer discovery and biosensor development space.
• BasePair Biotechnologies: BasePair offers custom aptamer and nucleic acid discovery services for diagnostics and therapeutics development. Direct CRO peer with similar aptamer discovery capabilities, though smaller in scale.
• CD Genomics (Biomarker CRO): CD Genomics offers biomarker discovery, validation, and custom assay development CRO services. Comparable in biomarker CRO service model with similar scientific research services offerings to pharma/diagnostics clients.

Emerging players

• Olink Holding: Olink provides proximity extension assay-based proteomics biomarker services with strong overlap in biomarker discovery and proteomic diagnostics for pharma/biotech clients. Comparable in target applications and customer base though it uses protein-binding rather than aptamer chemistry.

Broad incumbents

• Charles River Laboratories: Charles River is a large, established CRO with biomarker, biosafety, and diagnostics service lines. Broad incumbent that competes with Triera for pharma/biotech CRO budgets across multiple service modalities including biomarker discovery.
• Bio-Techne: Bio-Techne is a large life science tools and diagnostics company with reagent, antibody, and diagnostic product portfolios. Broad incumbent operating adjacent to Triera's diagnostic and biomarker detection markets.
• IQVIA: IQVIA is a global clinical and commercial CRO with diagnostics and biomarker service offerings. Broad incumbent that competes for enterprise pharma/biotech CRO spend; relevant because Triera targets the same customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/trierabiosciences

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triera Biosciences